All In Biotech

Drug Trial Radar · NCT07195695

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Beamion LUNG-3: A Randomized, Controlled, Multi-center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared With Standard of Care in Patients With Early-stage, Resectable Non-small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jan 16, 2026

Primary completion

Feb 26, 2032

Study completion Sep 2, 2036

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 29, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) mutations. Eligible participants must have undergone curative-intent surgery and received guideline-appropriate perioperative systemic therapy, either neoadjuvant platinum-based chemotherapy with or without immunotherapy, or adjuvant platinum-based chemotherapy. Participants are randomized 1:1 to receive zongertinib or standard of care, which may consist of approved adjuvant immunotherapy or active surveillance, based on local practice guidelines. The main purpose of the study is to determine whether zongertinib can prolong disease-free survival compared to standard treatment. Safety and patient-reported outcomes are also assessed.

Conditions

  • Non-small Cell Lung Cancer

Interventions

  • ZongertinibDrug

    Zongertinib

  • PembrolizumabDrug

    Pembrolizumab

  • AtezolizumabDrug

    Atezolizumab

  • DurvalumabDrug

    Durvalumab

  • NivolumabDrug

    Nivolumab

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease-free survival (DFS) by investigator's assessmentTime frame: up to 8 years and 5 months

Locations

205 sites in 28 countries. Site status is shown where the registry gives one.

  • ClinRé 001-022 (Premier Cancer Care and Infusion Center)

    Fresno, California · Recruiting

  • OPN Healthcare, Inc.

    Glendale, California · Recruiting

  • University of California Irvine

    Orange, California · Recruiting

  • Sutter Health

    Roseville, California · Recruiting

  • University of California San Francisco

    San Francisco, California · Recruiting

  • Sarcoma Oncology Center

    Santa Monica, California · Recruiting

  • University of California Los Angeles

    Santa Monica, California · Recruiting

  • Northern California Kaiser Permanente

    Vallejo, California · Not yet recruiting

  • George Washington University Cancer Center

    Washington D.C., District of Columbia · Not yet recruiting

  • Mid Florida Hematology and Oncology Center

    Orange City, Florida · Recruiting

  • Piedmont Cancer Institute

    Atlanta, Georgia · Recruiting

  • Northwest Georgia Oncology Centers

    Marietta, Georgia · Recruiting

  • Saint Alphonsus Regional Medical Center - Boise

    Boise, Idaho · Not yet recruiting

  • Northwestern University

    Chicago, Illinois · Not yet recruiting

  • University of Illinois Hospital and Health Sciences System

    Chicago, Illinois · Recruiting

  • Duly Health and Care - Lisle

    Lisle, Illinois · Recruiting

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Cancer Care Specialists

    Reno, Nevada · Recruiting

  • Laura & Isaac Perlmutter Cancer Center at NYU Langone Health

    New York, New York · Recruiting

  • Memorial Sloan-Kettering Cancer Center

    New York, New York · Recruiting

  • Levine Cancer Institute

    Charlotte, North Carolina · Recruiting

  • Durham VA Health Care System

    Durham, North Carolina · Not yet recruiting

  • Levine Cancer Institute

    Winston-Salem, North Carolina · Not yet recruiting

  • Providence Cancer Institute

    Portland, Oregon · Recruiting

  • Hendrick Health

    Abilene, Texas · Recruiting

  • Texas Oncology - Amarillo

    Amarillo, Texas · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Not yet recruiting

  • Community Cancer Trials of Utah

    Ogden, Utah · Recruiting

  • Virginia Cancer Specialists, PC

    Fairfax, Virginia · Recruiting

  • Centro de Investigaciones Medicas y Desarrollo LC S.R.L. (LC Investigacion)

    CABA, Argentina · Recruiting

  • Hospital Britanico de Buenos Aires

    CABA, Argentina · Recruiting

  • Centro Oncologico Korben

    CABA, Argentina · Recruiting

  • Clinica Adventista Belgrano

    CABA, Argentina · Recruiting

  • Instituto Medico Especializado Alexander Fleming

    Ciudad Autónoma de Bs As, Argentina · Recruiting

  • Austin Health

    Heidelberg, Australia · Recruiting

  • Royal North Shore Hospital

    Sydney, Australia · Recruiting

  • Princess Alexandra Hospital

    Woolloongabba, Australia · Recruiting

  • Flinders Medical Centre

    Bedford Park, South Australia, Australia · Recruiting

  • St John of God Subiaco Hospital

    Subiaco, Western Australia, Australia · Recruiting

  • Medical University of Innsbruck

    Innsbruck, Austria · Not yet recruiting

Showing 40 of 205 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.